It has been recently suggested that mutations in cancer susceptibility genes not normally considered primarily as determinants of CRC risk such as BRCA2 [6] and TP53 [7] contribute significantly to CRC and are of clinical utility. The gene discussed is BRCA2; the disease is cancer.